Long-term follow-up of patients with differentiated thyroid cancer who had negative 131i whole-body scan at first evaluation after treatment

Clinical Nuclear Medicine

Volumn 38, Issue 10, 2013, Pages 765-769

  Caminha, Luciana Souza Cruz ^a   Momesso, Denise Prado ^a   Vaisman, Fernanda ^a,b   Corbo, Rossana ^a,b   Vaisman, Mario ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Differentiated thyroid cancer; Follow up; Negative whole body scan

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; THYROGLOBULIN; THYROID HORMONE;

ABLATION THERAPY; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER RISK; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PRACTICE; DIFFERENTIATED THYROID CANCER; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LONG TERM CARE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; THYROIDECTOMY; TREATMENT RESPONSE; WHOLE BODY SCINTISCANNING; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; THYROGLOBULIN; THYROID NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 84897606058     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31829f8c71     Document Type: Article

References (26)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
2. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803.
3. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
4. Maia AL, Ward LS, Carvalho GA, et al. Thyroid nodules and differentiated thyroid cancer: Brazilian consensus. Arq Bras Endocrinol Metabol. 2007; 51:867-863.
5. Hundahl SA, Fleming ID, Fremgen AM, et al. A national cancer data base report on 53.856 cases of thyroid carcinoma treated in the US 1985-1995. Cancer. 1998;83:2638-2648.
6. DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71: 414-424.
7. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167.
8. Brito AS, Coeli CM, Barbosa FS, et al. Estimates of thyroid cancer incidence in Brazil: an approach using polynomial models. Cad Saúde Pública. 2011;27: 1441-1444.
9. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009;115:3801-3807.
10. Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid. 2006;16:45-53.
11. Hay ID, Hutchinson ME, Gonzalea-Losada T, et al. Papillary microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery. 2008;144: 980-988.
12. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341-1349.
13. Pacini F, Capezzone M, Elisei R, et al. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab. 2002;87: 1499-1501.
14. Verburg FA, Stokkel MP, Düren C, et al. No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37:276-283.
15. Brassard M, Borget I, Edet-Sanson A, et al. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab. 2011;96:1352-1359.
16. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981;70:511-518.
17. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:215.
18. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86: 1447-1463.
19. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879-885.
20. Vaisman F, Momesso D, Bulzico D, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf ). 2012;77:132-138.
21. Toubeau M, Touzery C, Arveux P, et al. Predictive value for disease progression for serum thyroglobulin levels measured in the postoperative period and after 131I ablation therapy with differentiated thyroid cancer. J Nucl Med. 2004;45:988-994.
22. Baudin E, Do Cao C, Cailleux AF, et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab. 2003;88:1107-1111.
23. Pacini F, Castagna MG. Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab. 2008;22:1009-1021.
24. Torlontano M, Attard M, Crocetti U, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab. 2004;89:3402-3407.
25. Hall NC, Kloos RT. PET imaging in differentiated thyroid cancer: where does it fit and how do we use it? Arq Bras Endocrinol Metabol. 2007;51: 793-805.
26. Shammas A, Degirmenci B, Mountz JM, et al. 18-F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med. 2007;48:221-226.